ArticleInternational journal of clinical oncology2021

Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.

Risa Motai et al.PubMed ↗Publisher ↗

No numbers read from the abstract.